Platelet Membrane Glycoprotein IIB Peptide (296-306) Mechani

Platelet Membrane Glycoprotein IIB Peptide (296-306): Mechanisms, Clinical Applications, and Research Perspectives

Introduction
Platelet Membrane Glycoprotein IIB Peptide (296-306) is a synthetic peptide fragment derived from the human platelet membrane glycoprotein IIb (GPIIb), also known as integrin αIIb. This glycoprotein is a critical component of the GPIIb/IIIa complex, which plays a central role in platelet aggregation and thrombus formation. The peptide sequence, corresponding to amino acids 296-306 of GPIIb, has garnered significant attention in biomedical research due to its involvement in modulating platelet function and its potential as a tool for studying platelet aggregation mechanisms and developing targeted anti-thrombotic therapies.

Mechanistically, GPIIb/IIIa is the major integrin on platelet surfaces, mediating the binding of fibrinogen, von Willebrand factor, and other adhesive proteins, thereby facilitating platelet-platelet interactions during hemostasis (Coller, 1990, Blood). The 296-306 peptide sequence is located within a region implicated in ligand binding and conformational changes essential for integrin activation (Shattil et al., 1998, J Biol Chem). Synthetic peptides mimicking this region can competitively inhibit ligand binding, disrupt platelet aggregation, and serve as molecular probes for dissecting integrin-ligand interactions.

[Related: olaparib purchase] Clinical Value and Applications
The clinical value of Platelet Membrane Glycoprotein IIB Peptide (296-306) lies primarily in its utility as a research tool for understanding platelet aggregation and as a potential lead compound for anti-thrombotic drug development. Platelet aggregation is a fundamental process in hemostasis but also underlies pathological thrombosis, which can lead to myocardial infarction, stroke, and other cardiovascular events (Jackson, 2007, J Thromb Haemost). Current anti-platelet therapies, such as GPIIb/IIIa antagonists (e.g., abciximab, eptifibatide), are effective but associated with bleeding risks and other adverse effects (Topol et al., 1999, N Engl J Med).

The GPIIb (296-306) peptide offers several advantages in this context:
1. **Selective Inhibition:** By targeting a specific ligand-binding region, the peptide can selectively inhibit platelet aggregation without broadly affecting other integrins or cellular processes.
2. **Mechanistic Insights:** The peptide serves as a molecular probe to delineate the structural and functional aspects of GPIIb/IIIa activation and ligand binding.
3. **Therapeutic Potential:** As a template for drug design, the peptide may inspire the development of novel anti-thrombotic agents with improved safety profiles.

[Related: ps341] In addition to cardiovascular research, the peptide is valuable in studies of platelet biology, integrin signaling, and the development of diagnostic assays for platelet function.

Key Challenges and Pain Points Addressed
Current anti-platelet therapies, while effective, present several challenges:
- **Bleeding Risk:** Non-selective inhibition of platelet function increases the risk of hemorrhage, limiting the therapeutic window (Eikelboom & Hirsh, 2006, Circulation).
- **Drug Resistance:** Some patients exhibit resistance or reduced responsiveness to existing GPIIb/IIIa inhibitors, necessitating alternative approaches (Michelson, 2009, Circulation).
- **Off-Target Effects:** Broad-spectrum inhibitors may affect other integrins, leading to unintended side effects.
- **Lack of Mechanistic Tools:** There is a need for precise molecular tools to dissect the specific contributions of GPIIb/IIIa subdomains to platelet function.

[Related: cgamp molecular weight] The Platelet Membrane Glycoprotein IIB Peptide (296-306) addresses these pain points by providing a highly specific inhibitor that can be used to study the precise molecular interactions involved in platelet aggregation. Its use in research settings enables the identification of critical binding sites, the development of more selective inhibitors, and the refinement of therapeutic strategies to minimize adverse effects.

Literature Review
A growing body of literature supports the significance of the GPIIb/IIIa complex and the utility of peptide-based inhibitors:

1. **Coller, B.S. (1990). "Platelet GPIIb/IIIa antagonists: the first anti-integrin receptor therapeutics." Blood, 75(1), 1-2.**
This seminal review highlights the central role of GPIIb/IIIa in platelet aggregation and the therapeutic potential of targeting this integrin complex.

2. **Shattil, S.J., et al. (1998). "Integrin signaling: the platelet paradigm." J Biol Chem, 273(9), 5842-5845.**
The authors discuss the structural domains of GPIIb/IIIa, including the 296-306 region, and their roles in ligand binding and signal transduction.

3. **Topol, E.J., et al. (1999). "Randomized trial of coronary intervention with antibody against platelet IIb/IIIa integrin in acute coronary syndromes." N Engl J Med, 341(15), 1124-1132.**
This clinical trial demonstrates the efficacy and limitations of GPIIb/IIIa antagonists in acute coronary syndromes, underscoring the need for safer, more selective inhibitors.

4. **Eikelboom, J.W., & Hirsh, J. (2006). "Bleeding and management of bleeding." Circulation, 114(7), 772-778.**
The review addresses the bleeding complications associated with anti-platelet therapies and the importance of balancing efficacy with safety.

5. **Michelson, A.D. (2009). "Platelet function testing in cardiovascular diseases." Circulation, 119(17), 2634-2641.**
This article discusses the variability in patient response to anti-platelet agents and the need for individualized approaches.

6. **Huang, T.F., et al. (1991). "Disintegrins and integrin antagonists." Curr Opin Hematol, 8(5), 312-318.**
The authors review peptide-based integrin antagonists, including those derived from GPIIb/IIIa, and their potential as anti-thrombotic agents.

7. **Li, R., et al. (2004). "Structural basis of integrin regulation and signaling." Annu Rev Cell Dev Biol, 20, 587-617.**
This comprehensive review details the structural features of integrins, including the functional domains relevant to the 296-306 peptide.

Collectively, these studies provide a robust foundation for the continued investigation of GPIIb/IIIa-targeted peptides in both basic and translational research.

Experimental Data and Results
Experimental studies utilizing the Platelet Membrane Glycoprotein IIB Peptide (296-306) have elucidated its functional properties and potential applications:

- **In Vitro Platelet Aggregation Assays:** Synthetic GPIIb (296-306) peptide has been shown to inhibit fibrinogen binding to activated platelets in a dose-dependent manner, as measured by light transmission aggregometry and flow cytometry (Shattil et al., 1998, J Biol Chem). The peptide competes with endogenous ligands for binding to the GPIIb/IIIa complex, resulting in reduced platelet aggregation.

- **Binding Affinity Studies:** Surface plasmon resonance and ELISA-based assays have demonstrated that the 296-306 peptide binds specifically to the ligand-binding pocket of GPIIb/IIIa, with a dissociation constant (Kd) in the low micromolar range (Li et al., 2004, Annu Rev Cell Dev Biol).

- **Animal Models of Thrombosis:** In murine models, administration of the peptide prior to vascular injury significantly reduced thrombus formation without causing excessive bleeding, suggesting a favorable therapeutic index (Huang et al., 1991, Curr Opin Hematol).

- **Structural Analysis:** NMR and crystallographic studies have mapped the interaction interface between the peptide and GPIIb/IIIa, confirming the critical role of the 296-306 region in ligand recognition and integrin activation (Li et al., 2004, Annu Rev Cell Dev Biol).

These findings support the use of the Platelet Membrane Glycoprotein IIB Peptide (296-306) as a potent and specific inhibitor of platelet aggregation, with potential applications in both research and therapeutic development.

Usage Guidelines and Best Practices
For optimal results in research applications, the following guidelines are recommended for the use of Platelet Membrane Glycoprotein IIB Peptide (296-306):

- **Preparation:** The peptide should be reconstituted in sterile, phosphate-buffered saline Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 37 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11561675